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Background: The ACTH stimulation test is used to evaluate the adrenocortical reserve. Recently, the availability of the
synthetic ACTH formulation was limited, causing major problems in clinical practice.
Objectives: The objective of this study was to evaluate poststimulation peak cortisol concentrations and the duration of
the stimulatory eﬀect of a depot ACTH preparation in dogs.
Animals: Twenty-two healthy dogs, 10 dogs with suspected hypoadrenocorticism (HA) and 15 dogs with suspected hyper-
adrenocorticism (HC).
Methods: Prospective study. An ACTH stimulation test using a synthetic depot tetracosactide, administered intramuscu-
larly (5 lg/kg or at least 0.1 mL) was performed. Blood samples for determination of cortisol were taken immediately before
and 1, 2, 3, 4, 6, and 24 hours after stimulation.
Results: Peak cortisol concentrations were reached after 2–4 hours in all dogs. Cortisol concentrations 1 hour after stimu-
lation were >9 lg/dL in all healthy dogs and >5 lg/dL in all dogs in which HA was excluded. None of the dogs with HA
showed a cortisol-increase above the detection-limit of the assay. After 6 hours, cortisol concentrations had decreased in the
healthy and HC group and were back to baseline after 24 hours.
Conclusions and Clinical Importance: The depot formulation can be used in place of the short-acting ACTH to evaluate
the adrenocortical reserve. Blood for peak cortisol concentrations should be drawn 3 hours after stimulation in cases in
which HC is suspected; in HA-suspected cases, blood sampling can take place after 1 hour. As the stimulatory eﬀect is gone
after 24 hours, interference with other hormonal tests is unlikely after that time.
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The ACTH stimulation test has traditionally beenrecognized as an accurate measure to assess the
functional reserve capacity of the adrenal cortex and
serves as gold standard in diagnosing hypoadrenocorti-
cism (HA) in dogs.1,2 The test is also used to distinguish
iatrogenic from spontaneous hyperadrenocorticism
(HC) and to monitor trilostane or mitotane treat-
ment.3,4
Several ACTH preparations are available. One of the
most commonly used formulations is a synthetic
polypeptide, which consists of the ﬁrst 24 (of a total 39)
amino acids of the ACTH, generally known as cosyn-
tropin or tetracosactide. Tetracosactide is available in 2
formulations: a short-acting form for IV or IM use and
a depot form for IM use only. The depot formulation
contains inorganic zinc complexes, which adsorb the
active substance, resulting in a protracted release.
Recently, the availability of the short-acting tetracosac-
tide was limited; in some countries it was not available
at all. In contrast, the availability of the depot formula-
tion has never been aﬀected.
In human medicine, the depot tetracosactide is used
for both therapeutic and diagnostic purposes. Among
other things, it has been described in the treatment of
rheumatoid arthritis, dermatosis (ie, pemphigus, psoria-
sis), or infantile myoclonic encephalopathy.5,6 To diag-
nose adrenal insuﬃciency, the depot tetracosactide is
used as a 5-hour test in which cortisol concentrations
are determined before and every hour after stimulation
for a 5-hour period.7 According to the manufacturer,
the duration of the stimulatory eﬀect of the depot tetra-
cosactide can be expected to last between 24 and
36 hours.
In veterinary medicine, the product has been evalu-
ated in healthy dogs using 2 diﬀerent concentrations
(5 lg/kg and 250 lg/dog) and blood sampling has been
performed during the ﬁrst 3 hours after stimulation.8
However, it is unknown whether peak serum cortisol
concentrations in dogs are reached 3 hours after stimu-
lation. In addition, the information as to what time
after stimulation cortisol concentrations are back to
baseline levels is lacking. Knowledge about the time of
peak cortisol concentration is a prerequisite for correct
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interpretation of the test and evaluation of adrenocorti-
cal reserve, and knowing the duration of the stimula-
tory eﬀect is important to assess the risk of interference
with other hormonal measurements. The use of the
depot ACTH preparation has not yet been evaluated in
dogs with adrenal diseases.
Therefore, the objective of this study was to evaluate
the depot tetracosactide preparation in healthy dogs
and in dogs with clinical signs consistent with HA or
HC, with the aims of determining the time point of
peak serum cortisol concentrations and the duration of
increased cortisol concentrations after tetracosactide
depot administration.
Materials and Methods
Animals
Twelve purpose-bred beagle-pinscher mixed-breed dogs (6
females and 6 males) with a median age of 2 years (range 1–
2 years) and a median body weight of 14.8 kg (range 13–17 kg)
were included. Dogs were housed in groups in standard kennels at
the research unit of the Vetsuisse Faculty of the University of Zur-
ich, fed a standard commercial maintenance pellet diet once daily,
and had ad libitum access to water.
In addition, 10 healthy privately owned dogs from hospital per-
sonnel and students, including 2 intact males and 8 females (5
spayed), with a median age of 5 years (range 1.5–12 years) and a
median body weight of 15.8 kg (range 6.9–27 kg) were used. They
were determined to be healthy on the basis of their history and
results of a physical examination plus hematologic and biochemi-
cal evaluation. None of the dogs had received any medication for
at least 8 weeks before inclusion in the study except routine vacci-
nation, deworming and heartworm prophylaxis.
Ten dogs with a clinical suspicion of HA were prospectively
enrolled. All dogs had initially been suspected of having HA based
on clinical signs or laboratory ﬁndings routinely seen in dogs with
HA, such as vomiting, diarrhea, weakness, lethargy, hyperkalemia
and hyponatremia. Blood and urine samples were collected for a
complete blood count, serum biochemical proﬁle and urinalysis.
Work-up included an ACTH stimulation test using the depot
preparation, which excluded HA when post-ACTH cortisol con-
centration was >5 lg/dL. Additional tests were abdominal ultra-
sonography (in particular adrenal glands) and measurement of
endogenous ACTH. There were 5 males (1 castrated) and 5
females (4 spayed). Their median age was 6 years (range 0.5–
14.0 years) and their median body weight 8.9 kg (range 4.9–
48 kg).
Fifteen dogs with a clinical suspicion of HC were prospectively
enrolled. Dogs previously treated with glucocorticoids, mineralo-
corticoids, progestagen, or trilostane were excluded from the
study. They all underwent a complete hematologic and biochemi-
cal evaluation, urinalysis including urinary culture, low-dose dex-
amethasone suppression test (LDDS test: 0.01 mg/kg
dexamethasone IV, blood sampling before, 4 and 8 hours there-
after), measurement of endogenous ACTH and an ultrasono-
graphic examination of the adrenal glands. Hyperadrenocorticism
was conﬁrmed when the LDDS test yielded a positive result
(serum cortisol concentration 8 hours after dexamethasone admin-
istration >1.0 lg/dL9–11) and treatment with trilostane showed an
appropriate response (starting dose of 2 mg/kg; re-evaluations per-
formed as described previously). Pituitary-dependent hyperadreno-
corticism (PDH) was diagnosed on the basis of the dogs’
concentration of endogenous ACTH and a symmetric ultrasono-
graphic appearance, with or without enlargement, of their adrenal
glands. There were 9 males (4 castrated) and 6 females (5 spayed).
Their median age was 10 years (range 7–15 years) and their med-
ian body weight 13.4 kg (range 3.6–45.0 kg).
Informed consent of all pet owners was obtained before includ-
ing the dogs in the study. Animal care was in accordance with the
guidelines and directives established by the Animal Welfare Act of
Switzerland. The study protocol was oﬃcially approved by the vet-
erinary oﬃce of the canton of Zurich and was in accordance with
the guidelines and directives established by the Animal Welfare
Act of Switzerland (TVB 191/2013).
Analytical Procedures
All dogs underwent an ACTH stimulation test using a synthetic
tetracosactide hexaacetate formulation with a concentration of
1,000 lg/mL.a For each test 5 lg/kg or at least 0.1 mL were
administered intramuscularly (supra/infraspinatus of the left/right
thoracic limb or quadriceps muscle of left/right hind limb) and
blood samples (jugular venipuncture) were taken immediately
before and 1, 2, 3, 4, 6, and 20–24 hours after stimulation. After
clot retraction at room temperature, serum was harvested by low-
speed centrifugation and transferred to tubes for storage at 20°C
for later hormone assay. Cortisol concentrations were measured
by chemiluminescence assay.b Sensitivity of the cortisol assay was
0.2 lg/dL. All samples of each dog were analyzed in the same run
to minimize interassay variation. Endogenous ACTH before
ACTH stimulation was determined by a chemiluminescence assay.b
Blood was collected into chilled EDTA-coated tubes placed on ice
and centrifuged at 4°C. Cortisol and endogenous ACTH measure-
ments were performed in house twice a week; plasma was stored
either at 20°C (cortisol) or at 80°C (ACTH) until assayed.
Immediately before analysis, samples were thawed at room
temperature.
Statistical Analyses
Data were analyzed with non-parametric statistical methods.c,d
Diﬀerences between groups of dogs were tested by using the
Kruskal–Wallis H-test and the Mann–Whitney U-test. Diﬀerences
between the time points of the ACTH stimulation were tested by
use of Friedman’s repeated measures test and the Wilcoxon
matched pairs test. All P values quoted are Bonferroni corrected.
The level of signiﬁcance was set at P < .05.
Results
No adverse reactions and no evidence of pain at the
injection site after IM administration were noticed in
any of the dogs during and after the stimulation test.
Healthy Dogs
Pre- and post-ACTH cortisol concentrations of all
time points of the healthy dogs are summarized in
Table 1. There was no signiﬁcant diﬀerence between the
values of healthy research dogs and healthy client-
owned dogs at any time point; therefore, all healthy
dogs were summarized in 1 group for further analysis.
Maximal median cortisol concentrations were reached
after 3 hours. Peak cortisol concentrations occurred
after 1 hour in 1, after 2 hours in 4, after 3 hours in 11
and after 4 hours in 6 dogs. Twenty-four hours after
stimulation cortisol concentrations had again reached
baseline concentrations. Cortisol concentrations 1, 2, 3,
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4, and 6 hours after stimulation were signiﬁcantly
higher than baseline cortisol concentrations (P: <.001,
<.001, <.001, <.001, and .002) and concentrations after
24 hours (P: <.001, <.001, <.001, <.001, and .002;
Fig 1).
Dogs with Clinical Suspicion of HA
Two dogs were diagnosed with primary HA (all post-
ACTH cortisol concentrations < 0.2 lg/dL, cACTH >
1,250 pg/mL) and 1 dog with iatrogenic HA (all post-
ACTH cortisol concentrations < 2.5 lg/dL, methylpred-
nisolone application by private veterinarian 4 weeks
previously). In 7 dogs, HA was excluded (post-
ACTH > 5 lg/dL; non-HA group). Pre- and post-
ACTH cortisol concentrations of the dogs with primary
HA, with iatrogenic HA and with non-HA are summa-
rized in Table 1.
In the non-HA group, maximal median cortisol con-
centrations were reached after 4 hours. Peak cortisol
concentrations occurred after 2 hours in 1, after 3 hours
in 1, and after 4 hours in 5 dogs. Cortisol concentra-
tions 1 and 3 hours after stimulation were signiﬁcantly
higher than baseline cortisol concentration (P = .036
and .036; Fig 2).
Dogs With Clinical Suspicion of HC
Pre- and post-ACTH cortisol concentrations of the
dogs with suspicion of HC are summarized in Table 1.
Maximal median cortisol concentrations were reached
after 3 hours. Peak cortisol concentration occurred after
1 hour in 1, after 2 hours in 5, after 3 hours in 6, and
after 4 hours in 2 dogs (1 dog missing). By 24 hours
after stimulation cortisol concentrations had again
reached baseline concentration. Cortisol concentrations
1, 2, 3, 4, and 6 hours after stimulation were signiﬁ-
cantly higher than baseline cortisol concentrations
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Fig 1. Serum cortisol concentrations before and after ACTH
stimulation with a synthetic ACTH depot formulation in healthy
dogs (n = 22). Each box represents the interquartile (ie, 25th to
75th percentile) range, the horizontal line within the box represents
the median value, the bars represent the 5th to 95th percentile,
and the circles represent outlying data points. Diﬀerent letters
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(P = .002, .002, .002, .006, and .026) and concentrations
after 24 hours (P = .01, .01, .016, .02, and .034)
(Fig 3A).
In 10 dogs, HC was conﬁrmed (all PDH; HC group)
and in 5 dogs HC was excluded (negative LDDS test
result; non-HC group). Two of these dogs were diag-
nosed with a hormonally inactive adrenal mass, 1 suf-
fered from diabetes mellitus and 2 dogs had PU/PD of
unclear origin. Cortisol concentrations at 24 hours after
stimulation were signiﬁcantly diﬀerent between the HC
and the non-HC group (P = .02; Fig 3B).
Comparison between Groups (Healthy, HC, Non-HC,
Non-HA)
The most distinctive diﬀerences were seen between
the healthy dogs and the HC dogs (all PDH). Baseline
cortisol and cortisol concentrations 1, 2, 3, 4, 6, and
24 hours after stimulation were signiﬁcantly higher in
dogs with HC compared with those in healthy dogs (P:
<.001, <.001, <.001, <.001, .002, .002 and <.001; Fig 4).
In the non-HC group, baseline and cortisol concen-
trations 1 and 24 hours after stimulation (P: <.001, .02,
and .01) and in the non-HA group, baseline cortisol
and cortisol concentrations 1 hour after stimulation
were signiﬁcantly diﬀerent from those of the healthy
dogs (P: .004 and .048; Fig 4).
Comparing the HC and the non-HA groups, cortisol
concentrations at 1 and 2 hours after stimulation were
signiﬁcantly diﬀerent (P = .01 and .032; Fig 4). Between
the non-HC and the non-HA groups, no diﬀerences
were detected.
Discussion
One of the goals of this study was to evaluate peak
cortisol concentrations after stimulation with depot
tetracosactide in healthy dogs and dogs with suspicion
of adrenal diseases. Peak median serum cortisol concen-
trations were reached after 3 hours in healthy dogs and
dogs with suspected HC and after 4 hours in dogs sus-
pected of having HA.
However, time point of peak cortisol concentration
varied individually lying between 1–4, 1–4, and 2–
4 hours in the healthy, non-HA group and in dogs sus-
pected of having HC, respectively. It is therefore impos-
sible to recommend an optimal sampling time point
after stimulation with which the peak cortisol concen-
trations of all adrenal diseases can be detected. How-
ever, considering the objective in performing an ACTH
stimulation test, it is diﬀerent for hypo- and hyperfunc-
tioning adrenal glands. In dogs suspected of suﬀering
from HA, the goal is either to exclude HA with a
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Fig 2. Serum cortisol concentrations before and after ACTH
stimulation with a synthetic ACTH depot formulation in dogs
with initial suspicion of hypoadrenocorticism (HA), but in which
HA was excluded (n = 7). Each box represents the interquartile
(ie, 25th to 75th percentile) range; the horizontal line within the
box represents the median value; the bars represent the 5th to 95th
percentile; the circles represent outlying data points. Diﬀerent let-
ters indicate statistically signiﬁcant diﬀerences between the time
points (P < .05).
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Fig 3. (A) Serum cortisol concentrations before and after ACTH
stimulation with a synthetic ACTH depot formulation in dogs
with clinical suspicion of hyperadrenocorticism (HC; n = 15). Each
box represents the interquartile (ie, 25th to 75th percentile) range;
the horizontal line within the box represents the median value; the
bars represent the 5th to 95th percentile; the circles represent out-
lying data points. Diﬀerent letters indicate statistically signiﬁcant
diﬀerences between the time points (P < .05). (B) Median and
range of serum cortisol concentrations before and after ACTH
stimulation with a synthetic ACTH depot formulation in dogs
with conﬁrmed HC (n = 10) and dogs with suspicion of HC but
normal low-dose dexamethasone suppression (LDDS) test (non-
HC, n = 5). *Signiﬁcant diﬀerence between the 2 groups.
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suﬃcient stimulation (post-ACTH cortisol > 5 lg/dL)
or to conﬁrm HA by an insuﬃcient stimulation (post-
ACTH cortisol < 2 lg/dL). This goal would have been
reached in our study, if blood had been taken already
1 hour after stimulation. All dogs suspected of having
HA but in which it was excluded had a 1-hour cortisol
concentration of >9 lg/dL; in those with conﬁrmed HA
it was <0.2 lg/dL. In addition, all healthy dogs had a
1-hour cortisol concentration >5 lg/dL. Therefore, it
could be concluded that for the diagnosis of HA in
dogs, using the depot tetracosactide, a blood sample
before and 1 hour after stimulation with 5 lg/kg is suf-
ﬁcient. This information is of great importance, because
if there is high suspicion of HA and the dog is in criti-
cal clinical condition, administration of corticosteroids
should not be delayed. Exogenous synthetic corticos-
teroids, however, can cross-react with cortisol assays or
bear the risk of adrenal gland suppression due to the
negative feedback mechanism, which as a consequence
would lead to blunted stimulation and misinterpretation
of the test.
The objective of an ACTH stimulation test in dogs
suspected of having HC and in which trilostane treat-
ment has to be monitored is diﬀerent. In these situa-
tions, knowledge of the peak cortisol concentration
after stimulation is the important information. From
our data, blood for the diagnosis of HC should be
drawn between 2 and 4 hours after stimulation, as
within this time period the likelihood of getting the
peak cortisol concentration is highest. Blood sampling
after 1 hour in these cases might lead to a falsely low
test result. Based on our data, no conclusion can be
drawn as to which time point should be chosen for
monitoring the trilostane treatment, as these dogs were
not evaluated. It is merely speculative that in these
cases, the 1-hour value might also be too early to assess
the maximal suppression of the cortisol synthesis during
trilostane treatment. Further studies are needed to
address this issue.
Another aspect of peak cortisol concentration is the
magnitude of the peak. Two of the healthy dogs had
post-ACTH cortisol values above the originally estab-
lished normal reference interval, with values of 23.2 and
26.3 lg/dL. Also, in individual dogs with suspected
HA, cortisol concentrations of up to 30 lg/dL could be
observed. Although these high values could be inter-
preted as being consistent with HC, none of the healthy
and certainly none of the HA-suspected dogs had clini-
cal signs suggestive of HC. In agreement with our data,
the study of Ginel et al8 evaluating depot tetracosactide
in healthy Greyhounds revealed peak cortisol concen-
trations with values up to 30 lg/dL. One might assume
that the depot product itself could lead to higher corti-
sol concentrations compared to the short-acting ACTH.
However, a study evaluating short-acting ACTH for the
diagnosis of HA in dogs reported similar results.12
Values for their dogs, using a dose of 5 lg/kg, reached
cortisol concentrations of up to 27.3 lg/dL; 1 dog even
had a value of 41.6 lg/dL without any evidence of HC
and with a ﬁnal diagnosis of inﬂammatory bowel dis-
ease. Therefore, we think it is more likely that the
increased response could have been caused by stress
(white-coat eﬀect) of the hospitalization and the blood
sampling, or it could be a sign of the concurrent illness
of the dogs.
A further interesting and important ﬁnding was that
peak cortisol concentrations reached values of >22 lg/
dL in 2 of the 5 dogs where HC was suspected but not
conﬁrmed, which according to published reference val-
ues should be considered abnormal.3,13,14 However,
these reference values were established using older and
diﬀerent assays. Care must be taken in adapting these
reference values, as it is possible that the magnitude of
peak concentration can reﬂect diﬀerences in the assays
used to measure cortisol. In human medicine, it was
shown that cortisol results from the same ACTH test
are quite diﬀerent when measured by 4 commonly used
assays.15 For the same cut-oﬀ value, it was possible to
have a negative test result with one and a positive result
with another assay. The authors concluded that estab-
lishing “normal peak” responses rely on the assay that
is used. This is likely to be the case in veterinary medi-
cine as well. Therefore, criteria for test interpretation
probably need to be reestablished and the cut-oﬀ level
for an abnormal test result should be newly deﬁned
with the currently used assays. This has already been
suggested in the consensus statement of the ACVIM
about the diagnosis of spontaneous canine HC.4
A second goal of this study was to assess the dura-
tion of increased cortisol concentrations after depot
tetracosactide administration. We were able to show
that after 24 hours the plasma cortisol concentrations
were back to baseline levels in both the healthy dogs
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Fig 4. Serum cortisol concentrations before and after ACTH
stimulation in healthy dogs (healthy, n = 22), dogs with hypera-
drenocorticism (HC, n = 10), dogs with initial suspicion of HC,
but negative low-dose dexamethasone suppression (LDDS) test
results (non-HC, n = 5), dogs with initial suspicion of hypoadreno-
corticism (HA), but normal ACTH stimulation (non-HA, n = 7),
dog with iatrogenic HA (iHA, n = 1) and dogs with primary HA
(primary HA, n = 2). For healthy, HC, non-HC and non-HA,
median and range are reported. For iHA and HA, single values of
each individual are reported. Statistical comparison was performed
between healthy, HC, non-HC and non-HA, only. aSigniﬁcant dif-
ference to healthy dogs, bsigniﬁcant diﬀerence to non-HA dogs.
#aaaApplies to HC, non-HC and non-HA. ##aaBelongs to HC and
non-HC.
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and patient groups. This is of importance, as especially
in dogs with suspected HC, a long duration of increased
cortisol concentrations after ACTH administration car-
ries the risk of interference with a LDDS test that may
be performed the next day. In human medicine, plasma
ACTH concentrations have been determined in healthy
volunteers after the administration of depot ACTH.16
While with the use of the short-acting ACTH prepara-
tion, ACTH concentrations dropped to undetectable
levels 2 hours after injection, the use of the depot
preparation led to increased plasma concentrations up
to 8 hours after administration.16 However, levels were
undetectable after 24 hours in all subjects.16 This ﬁnd-
ing is somewhat reﬂected in our data: although we did
not determine plasma ACTH concentrations, we
observed a substantially decreased cortisol concentra-
tion after 6 hours as compared to 3 hours and, as men-
tioned above, values were back to baseline
concentrations after 24 hours. Interestingly, dogs with
conﬁrmed HC still had higher cortisol concentrations
after 24 hours compared to dogs in which HC was
excluded. This shows that in dogs with hyperfunction-
ing adrenal glands, exogenous ACTH can result in pro-
tracted cortisol secretion in comparison with dogs with
normal adrenal function. Alternatively, it can reﬂect a
decreased cortisol clearance in dogs with HC.
In conclusion, our data show that the depot tetracos-
actide may be used in place of the short-acting product
for evaluation of the hypothalamic–pituitary–adrenal
axis in dogs with adrenal malfunction. Blood sampling
can take place 1 hour after stimulation in dogs with
suspected HA. However, special attention has to be
paid in the diagnostic evaluation of HC, as blood sam-
pling 1 hour after stimulation does not reveal maximal
stimulation. Nonetheless, the LDDS test can be per-
formed 24 hours after depot tetracosactide administra-
tion without risk of interference.
Footnotes
a Synacthen Depot, Novartis Pharma Schweiz AG, Bern,
Switzerland
b DPC Immulite 1,000, Siemens Schweiz AG, Zurich, Switzer-
land
c GraphPad Prism6, Graph Pad Software, San Diego, CA, USA
d SPSS 22.0 for Windows, SPSS Inc, Chicago, IL, USA
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